Cognition Therapeutics 향후 성장

Future 기준 점검 0/6

Cognition Therapeutics 의 수익은 연간 30.4% 감소할 것으로 예상되는 반면, 연간 수익은 64.7% 로 증가할 것으로 예상됩니다. EPS는 연간 6.6% 만큼 쇠퇴할 것으로 예상됩니다.

핵심 정보

-30.4%

이익 성장률

-6.62%

EPS 성장률

Pharmaceuticals 이익 성장	14.5%
매출 성장률	64.7%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	28 May 2026

최근 향후 성장 업데이트

Recent updates

분석 기사 • Mar 28

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

새로운 내러티브 • Mar 26

DLB Psychosis Program And Biomarker Strategy Will Shape Long Term Upside Potential

Catalysts About Cognition Therapeutics Cognition Therapeutics is a clinical stage biopharmaceutical company focused on developing zervimesine for neurodegenerative diseases such as dementia with Lewy bodies and Alzheimer's disease. What are the underlying business or industry changes driving this perspective?

분석 기사 • Nov 12

We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, Cognition...

분석 기사 • Jul 04

We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

분석 기사 • Dec 20

Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

분석 기사 • Sep 06

Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Jul 31

Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease

Summary Cognition Therapeutics' stock dropped over 40% after Phase 2 trial results for Alzheimer's disease. Results showed cognitive benefit but fading statistical significance over time. CT1812 did not outperform placebo on all rating scales over 3-6 months, raising concerns for future milestones and larger trials. Financial reliance on NIH grants poses risks, and ongoing trials in dementia with Lewy Bodies, Alzheimer's and dry AMD have the potential for further stock decline. Read the full article on Seeking Alpha

분석 기사 • May 22

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Apr 18

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

Summary Cognition Therapeutics is set to report topline data from its Phase 2 trial in Alzheimer's disease in mid-2024. CT1812, the company's lead drug candidate, is a sigma-2 receptor antagonist for Alzheimer's and aims to prevent the binding of toxic Aβ oligomers. Preliminary data from the ongoing SHINE trial showed some interesting results, but were not consistent with other previous studies, raising caution about the upcoming data. At a ~$70 million market cap with about half of that cash, the topline readout could be a binary event for the stock. Read the full article on Seeking Alpha

분석 기사 • Nov 30

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

분석 기사 • Aug 15

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

분석 기사 • Mar 17

Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Sep 27

Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study

Cognition Therapeutics (NASDAQ:CGTX) said it received a $2.14M grant from the National Institute on Aging (NIA) to help complete an ongoing study of CT1812 in adults with mild-to-moderate Alzheimer's disease. The study called SEQUEL will evaluate if CT1812 results in a normalization of the EEG patterns. The trial is enrolling 16 adults who will receive either CT1812 or placebo, the company said in a Sept. 27 press release. Cognition noted that the study is taking place at the Amsterdam UMC Dept. of Neurology/Alzheimer Center and Brain Research Center. The NIA, a division of the National Institutes of Health (NIH), awarded a $3.2M grant in 2020 to support the study and has now awarded $2.14M, the company added. CGTX +12.28% to $1.92 premarket Sept. 27

분석 기사 • Aug 12

We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Aug 05

Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar

An analysis of biomarker data from Cognition Therapeutics' (NASDAQ:CGTX) Alzheimer's disease candidate CT1812 indicate the oral once-daily treatment supports a synaptoprotective mechanism of action and has a role in normalizing cellular processes. Proteomic analyses demonstrated CT1812's impact on several Alzheimer's biomarkers, including YKL-40, which is an indicator of inflammation and is upregulated in the disease. Results showed that participants given CT-1812 saw declining levels of YKL-40. The candidate also had a significant impact on cerebrospinal fluid levels of clusterin, a genetic risk factor for Alzheimer's. Cognition closed up 62% on Thursday but is down 16% in Friday premarket trading.

분석 기사 • Mar 19

We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

이익 및 매출 성장 예측

NasdaqCM:CGTX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	N/A	-103	-91	N/A	1
12/31/2027	N/A	-34	-64	N/A	3
12/31/2026	N/A	-32	-58	N/A	4
3/31/2026	N/A	-20	N/A	N/A	N/A
12/31/2025	N/A	-23	-25	-25	N/A
9/30/2025	N/A	-28	-30	-30	N/A
6/30/2025	N/A	-33	-31	-31	N/A
3/31/2025	N/A	-33	-31	-31	N/A
12/31/2024	N/A	-34	-28	-28	N/A
9/30/2024	N/A	-34	-26	-26	N/A
6/30/2024	N/A	-31	-23	-23	N/A
3/31/2024	N/A	-29	-21	-21	N/A
12/31/2023	N/A	-26	-16	-16	N/A
9/30/2023	N/A	-23	-21	-21	N/A
6/30/2023	N/A	-23	-17	-17	N/A
3/31/2023	N/A	-24	-18	-18	N/A
12/31/2022	N/A	-21	-19	-19	N/A
9/30/2022	N/A	-24	-8	-8	N/A
6/30/2022	N/A	-22	-10	-10	N/A
3/31/2022	N/A	-19	-6	-6	N/A
12/31/2021	N/A	-16	-4	-4	N/A
9/30/2021	N/A	-12	-4	-4	N/A
6/30/2021	N/A	-10	-3	-3	N/A
3/31/2021	N/A	-9	-5	-5	N/A
12/31/2020	N/A	-12	-3	-3	N/A

애널리스트 향후 성장 전망

수입 대 저축률: CGTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CGTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CGTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CGTX 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 매출: CGTX 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: CGTX의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/28 22:14
종가	2026/05/28 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Cognition Therapeutics, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Mayank Mamtani	B. Riley Securities, Inc.
null null	B. Riley Securities, Inc.
William Wood	B. Riley Securities, Inc.

Cognition Therapeutics 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 7.7% to US$3.50

Price target decreased by 11% to US$5.60

Price target decreased by 19% to US$6.25

Price target decreased by 26% to US$7.75

Price target decreased by 8.7% to US$10.50

Price target decreased to US$11.50

Recent updates

Cognition Therapeutics, Inc. Completes Meeting With FDA For Zervimesine (CT1812) In Dementia With Lewy Bodies With Psychosis

New minor risk - Market cap size

Cognition Therapeutics, Inc., Annual General Meeting, Jun 17, 2026

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

New major risk - Financial position

DLB Psychosis Program And Biomarker Strategy Will Shape Long Term Upside Potential

Cognition Therapeutics, Inc. to Report Q4, 2025 Results on Mar 26, 2026

Cognition Therapeutics Presents Evidence Of Zervimesine’s Impact On Neuropsychiatric Symptoms Of Dementia With Lewy Bodies

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (Ct1812) in Dementia with Lewy Bodies

New minor risk - Market cap size

Cognition Therapeutics, Inc. Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics, Inc. Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease Conference

Price target increased by 7.7% to US$3.50

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (Ct1812) in Early Alzheimer's Disease

We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

New major risk - Financial position

Cognition Therapeutics, Inc. Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target

Cognition Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $30.135 million.

Cognition Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $30.135 million.

Cognition Therapeutics, Inc. Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease

Cognition Therapeutics, Inc. Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

Cognition Therapeutics, Inc. Announces Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) to Be Presented in A Podium Presentation at AAIC

Cognition Therapeutics Completes End-Of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease

We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

New major risk - Share price stability

Cognition Therapeutics, Inc. Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)

Cognition Therapeutics, Inc. Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy

Insufficient new directors

Cognition Therapeutics, Inc., Annual General Meeting, Jun 18, 2025

Cognition Therapeutics, Inc. Presents Results At AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

New major risk - Shareholder dilution

Price target decreased by 11% to US$5.60

Insufficient new directors

Cognition Therapeutics, Inc. to Report Q4, 2024 Results on Mar 20, 2025

Cognition Therapeutics Successfully Passes Pre-Defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy

Cognition Therapeutics, Inc. Announces Positive Phase 2 'Shimmer' Study of Zervimesine (Ct1812) in Dementia with Lewy Bodies (Dlb) Will Be Presentation At Ilbdc

Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely

Cognition Therapeutics, Inc. Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Cognition Therapeutics Announces All Participants Completes Their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Cognition Therapeutics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?

Cognition Therapeutics, Inc. Publishes EEG Findings from Phase 2QUEL Study of CT1812 in Mild-to-Mod Moderate Alzheimer's Disease

Cognition Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease

Cognition Therapeutics, Inc’s Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients

Cognition Therapeutics, Inc. Announces Results from Cognition Therapeutics' Phase 2 Shine Study of CT1812 in Mild-To-Moderate Alzheimer's Disease Accepted for Presentation at AAIC

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

New major risk - Financial position

Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

Cognition Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

Cognition Therapeutics, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Cognition Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $11.499999 million.

Cognition Therapeutics, Inc. Presents Analyses at AD/PD 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-To-Mod Moderate Alzheimer's Disease

Cognition Therapeutics, Inc. Appoints Quang Pham as Board Director

Cognition Therapeutics, Inc. and Collaborators At Yale and ACTC Announce Oral Late-Breaking Presentation on the Start Study in Early Alzheimer’s Disease At CTAD

Cognition Therapeutics, Inc. Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease At CTAD

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Price target decreased by 19% to US$6.25

Cognition Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Share price stability

Cognition Therapeutics, Inc. and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 Start Study in Early Alzheimer's Disease

Cognition Therapeutics, Inc. Announces Positive Topline Results for CT1812 Phase 2 Sequel Study for Mild-To-Moderate Alzheimer’s Disease